EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Joel Neal iD, Nick Pavlakis iD, Sang-We Kim, Yasushi Goto iD, Sun Min Lim iD, Giannis Mountzios iD, Elena Fountzilas iD, Anastasia Mochalova, Daniel C Christoph iD, Alessandra Bearz iD, Xavier Quantin iD, Ramon Palmero iD und 10 weitere

Journal of Clinical Oncology · 10.07.2024 · 42 (20) · 2393-2403

DOI: 10.1200/jco.23.02166 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2024. Verfasst von Joel Neal und 21 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Institute, Stanford University, Palo Alto, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Docetaxel, Antibodies, Monoclonal, Humanized, Lung Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti–PD-L1/PD-1 immunotherapy. CONTACT-01 (ClinicalTrials.gov identifier: NCT04471428 ) evaluated atezolizumab plus cabozantinib versus docetaxel in patients with metastatic NSCLC who developed disease progression after concurrent or sequential treatment with anti–PD-L1/PD-1 and platinum-containing chemotherapy. METHODS This multicenter, open-label, phase III trial randomly assigned patients 1:1 to atezolizumab 1,200 mg intravenously once every 3 weeks (q3w) plus cabozantinib 40 mg orally once daily or docetaxel 75 mg/m 2 intravenously once every 3 weeks. The primary end point was overall survival (OS). RESULTS One hundred eighty-six patients were assigned atezolizumab plus cabozantinib, and 180 docetaxel. Minimum OS follow-up was 10.9 months. Median OS was 10.7 months (95% CI, 8.8 to 12.3) with atezolizumab plus cabozantinib and 10.5 months (95% CI, 8.6 to 13.0) with docetaxel (stratified hazard ratio [HR], 0.88 [95% CI, 0.68 to 1.16]; P = .3668). Median progression-free survival was 4.6 months (95% CI, 4.1 to 5.6) and 4.0 months (95% CI, 3.1 to 4.4), respectively (stratified HR, 0.74 [95% CI, 0.59 to 0.92]). Serious adverse events (AEs) occurred in 71 (38.4%) patients receiving atezolizumab plus cabozantinib and 58 (34.7%) receiving docetaxel. Grade 3/4 treatment-related AEs occurred in 73 (39.5%) patients receiving atezolizumab plus cabozantinib and 58 (34.7%) receiving docetaxel. Grade 5 AEs occurred in 14 (7.6%) and 10 (6.0%) patients in the atezolizumab plus cabozantinib and docetaxel arms, respectively (treatment-related in four [2.2%] and one [0.6%], respectively). CONCLUSION Atezolizumab plus cabozantinib after disease progression following anti–PD-L1/PD-1 immunotherapy and platinum-containing chemotherapy for metastatic NSCLC did not improve OS compared with docetaxel. Safety was consistent with known profiles of these agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDocetaxelAntibodies, Monoclonal, HumanizedLung NeoplasmsPyridinesAnilidesAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overProgression-Free Survival

Substanzen

atezolizumabDocetaxelAntibodies, Monoclonal, HumanizedcabozantinibPyridinesAnilidesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Stanford Cancer Institute, Stanford University, Palo Alto, CA.
  • Royal North Shore Hospital, University of Sydney, St Leonards, Australia.
  • Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
  • National Cancer Center, Tokyo, Japan.
  • Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Henry Dunant Hospital Center, Athens, Greece.

ORCID-Profile: Joel Neal, Nick Pavlakis, Yasushi Goto, Sun Min Lim, Giannis Mountzios, Elena Fountzilas, Daniel C Christoph, Alessandra Bearz, Xavier Quantin, Ramon Palmero, Ya-Chen Lin

Zitieren

APA

Neal, J., Pavlakis, N., Kim, S. W., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A., Christoph, D. C., Bearz, A., Quantin, X., Palmero, R., Antic, V., Chun, E., Edubilli, T. R., Lin, Y. C., Huseni, M., Ballinger, M., Graupner, V., …, & Newsom-Davis, T. (2024). CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. Journal of Clinical Oncology, 42(20), 2393-2403. https://doi.org/10.1200/jco.23.02166

Vancouver

Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. Journal of Clinical Oncology. 2024;42(20):2393-2403. doi:10.1200/jco.23.02166

BibTeX
@article{Neal2024,
  author = {Neal, Joel and Pavlakis, Nick and Kim, Sang-We and Goto, Yasushi and Lim, Sun Min and Mountzios, Giannis and Fountzilas, Elena and Mochalova, Anastasia and Christoph, Daniel C and Bearz, Alessandra and Quantin, Xavier and Palmero, Ramon and Antic, Vladan and Chun, Elaine and Edubilli, Tirupathi Rao and Lin, Ya-Chen and Huseni, Mahrukh and Ballinger, Marcus and Graupner, Vilma and Curran, Dominic and Vervaet, Piet and Newsom-Davis, Thomas},
  title = {CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {20},
  pages = {2393--2403},
  doi = {10.1200/jco.23.02166}
}
Kostenlos starten →